Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

61 results about "HDAC6" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Histone deacetylase 6 is an enzyme that in humans is encoded by the HDAC6 gene.

3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors

ActiveUS20160304462A1Useful in treatmentImproved profileNervous disorderOrganic chemistryProliferative diseaseAutoimmune disease

The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors

3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors

3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors

Owner:VALO HEALTH INC

3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

ActiveUS20160222028A1Useful in treatmentOrganic active ingredientsNervous disorderDiseaseHydroxamic acid

The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

Owner:VALO HEALTH INC

3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

ActiveUS20160221972A1Useful in treatmentOrganic active ingredientsNervous disorderDiseaseHDAC6

The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:

where R, L, X¹, X², X³, X⁴, Y¹, Y², Y³, and Y⁴are described herein.

3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

Owner:VALO HEALTH INC

Histone deacetylase 6 (HDAC6) biomarkers in multiple myeloma

InactiveUS20150176076A1Effective treatmentOrganic active ingredientsBiocideDrug specific IgEBiomarker (petroleum)

The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.

Histone deacetylase 6 (HDAC6) biomarkers in multiple myeloma

Histone deacetylase 6 (HDAC6) biomarkers in multiple myeloma

Histone deacetylase 6 (HDAC6) biomarkers in multiple myeloma

Owner:ACETYLON PHARMA

Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors

ActiveUS20150239869A1Organic active ingredientsBiocideDiseaseHDAC6

The present invention relates to pyrimidine hydroxy amide compounds, the use of such compounds in the inhibition of HDAC6, and the use of such compounds in the treatment of various diseases, disorders, or conditions related to HDAC6.

Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors

Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors

Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors

Owner:ACETYLON PHARMA

3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors

ActiveUS20190185462A1Group 4/14 element organic compoundsNervous disorderDitazoleAryl

The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.

3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors

3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors

3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors

Owner:MERCK SHARP & DOHME LLC

2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors

ActiveUS20200121655A1Improved profileOrganic active ingredientsNervous disorderAutoimmune conditionHydroxamic acid

The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors

2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors

2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors

Owner:VALO HEALTH INC

Metalloenzyme inhibitor compounds

ActiveUS20180256572A1Improved pharmacokinetic profileOrganic active ingredientsOrganic chemistryDiseaseMedicine

Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.

Metalloenzyme inhibitor compounds

Metalloenzyme inhibitor compounds

Metalloenzyme inhibitor compounds

Owner:EIKONIZO THERAPEUTICS INC

Methods and compositions for regulating hdac6 activity

InactiveUS20100292169A1BiocideTissue cultureHDAC6Cancer research

The present invention provides methods and compositions for inhibiting Hsp90 activity in a cell, comprising contacting the cell with an inhibitor of histone deacetylase 6 (HDAC6)

Methods and compositions for regulating hdac6 activity

Methods and compositions for regulating hdac6 activity

Methods and compositions for regulating hdac6 activity

Owner:DUKE UNIV

2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors

ActiveUS10555935B2Improved profileOrganic active ingredientsNervous disorderAutoimmune conditionHydroxamic acid

The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors

2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors

2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors

Owner:VALO HEALTH INC

Application of inhibitor of histone deacetylase HDAC 6 in preparing drugs for preventing and treating acute kidney injury

InactiveCN107158390AProtective structureProtective functionOrganic active ingredientsUrinary disorderInflammatory factorsAkt signalling

The invention provides an application of inhibitor of histone deacetylase HDAC 6 in preparing drugs for preventing and treating acute kidney injury. Furthermore, the histone deacetylase HDAC 6 is Tubastatin A. The selective inhibitor of HDAC 6 can lighten the renal pathology damage of acute kidney injury induced by cis-platinum and improve the kidney function. The HDAC6 inhibitor TA can lower the release of inflammatory factors and lighten the oxidative stress reaction through regulating an AKT signal access, an NF-KB inflammation access, an autophagy level and an E-cadherin expression; thus the apoptosis of kidney tubule cell and necrosis of tubule expansion are reduced, the renal pathology damage and kidney function are improved; the inhibitor can protect the kidney structure and function in the acute kidney injury. Therefore, HDAC6 is likely to be an important target point to prevent and treat the acute kidney injury.

Application of inhibitor of histone deacetylase HDAC 6 in preparing drugs for preventing and treating acute kidney injury

Application of inhibitor of histone deacetylase HDAC 6 in preparing drugs for preventing and treating acute kidney injury

Application of inhibitor of histone deacetylase HDAC 6 in preparing drugs for preventing and treating acute kidney injury

Owner:SHANGHAI EAST HOSPITAL

HDAC6 selective inhibitors, preparation method therefor, and application thereof

ActiveUS10745389B2Remarkable in vitro activityRemarkable effectOrganic chemistryBoron compound active ingredientsDiseaseHDAC6

Compounds serving as histone deacetylase 6 (HDAC6) selective inhibitors, and applications thereof in the preparation of drugs for treating HDAC6-related diseases. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.

HDAC6 selective inhibitors, preparation method therefor, and application thereof

HDAC6 selective inhibitors, preparation method therefor, and application thereof

HDAC6 selective inhibitors, preparation method therefor, and application thereof

Owner:CSTONE PHARM (SUZHOU) CO LTD +2

1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

ActiveUS10464911B2Prevent goodConvenient treatmentNervous disorderOrganic chemistryNervous systemNeoplasm

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.

1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Owner:CHONG KUN DANG PHARMA CORP

1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same

ActiveUS10584117B2Good effectOrganic active ingredientsSenses disorderDitazoleRespiratory disease

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.

1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same

1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same

1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same

Owner:CHONG KUN DANG PHARMA CORP

Hydroxamic acid compound and application thereof

ActiveCN114315754APrevent proliferationProliferation inhibitory effect is significantOrganic chemistryAntineoplastic agentsCancer preventionHydroxamic acid

The invention relates to the field of medical chemistry, in particular to a hydroxamic acid compound containing substituted 2-phenylthiazole-5-formamide or 2-phenylimidazole-5-formamide and application of the hydroxamic acid compound, the compound has a structure as shown in a formula (I), can selectively act on HDAC6, inhibit cancer cell proliferation and enhance tumor immunity, and can be used for preparing an HDAC6 drug or an HDAC6 drug or an HDAC6 drug or an HDAC6 drug or an HDAC6 drug or an HDAC6 drug or an HDAC6 drug. The compound has efficient anti-cancer activity. Therefore, the compound can be used for preparing histone deacetylase inhibitors and drugs for treating and/or preventing cancers.

Hydroxamic acid compound and application thereof

Hydroxamic acid compound and application thereof

Hydroxamic acid compound and application thereof

Owner:SOUTHERN MEDICAL UNIVERSITY

1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

ActiveUS10538498B2Prevent goodConvenient treatmentNervous disorderOrganic chemistryDitazoleDisease

The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.

1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Owner:CHONG KUN DANG PHARMA CORP

Methods for nucleic acid transfer into cells

ActiveUS8334272B2Sugar derivativesMicrobiological testing/measurementHDAC6Gene transfer

The present invention provides methods for increasing the transfer of nucleic acids into cells. In particular, the present invention provides for the use of inhibitors of HDAC6, a cytoplasmic histone deacetylase present in mammalian cells by, for example, small molecules or siRNA treatment, in increasing gene transfer and / or expression in cells in vitro and in vivo for research and gene therapy applications.

Methods for nucleic acid transfer into cells

Methods for nucleic acid transfer into cells

Methods for nucleic acid transfer into cells

Owner:NORTHWESTERN UNIV

Histone deacetylase 6 (HDAC6) biomarkers in multiple myeloma

InactiveUS20200405716A1Organic active ingredientsMicrobiological testing/measurementDrug specific IgEHDAC6

The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.

Histone deacetylase 6 (HDAC6) biomarkers in multiple myeloma

Histone deacetylase 6 (HDAC6) biomarkers in multiple myeloma

Histone deacetylase 6 (HDAC6) biomarkers in multiple myeloma

Owner:ACETYLON PHARMA

Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching

InactiveUS20210077487A1Effectively inhibiting and treating itchingOrganic active ingredientsDermatological disorderHDAC6Pharmaceutical drug

The present invention relates to a pharmaceutical composition containing an HDAC6 inhibitor as an active ingredient for prevention or treatment of itching. The present invention provides a novel pharmaceutical composition containing, as an active ingredient, an inhibitor for inhibiting an HDAC6 enzyme, and thus can effectively inhibit and treat itching caused by trypsin, tryptase, histamine, antimycin A, chloroquine, or the like.

Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching

Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching

Owner:BNH RES CO LTD

Biomarkers for prognosis

InactiveUS20160069887A1Increased susceptibilityLower Level RequirementsMicrobiological testing/measurementDisease diagnosisHDAC6Cell survival

The invention relates to biomarkers for determining the prognosis of cancer patients. By determining the level of the biomarker HR23B in the cell or patient, and optionally determining the levels of one or more of the biomarkers HDAC6, LC3 and HSP90, the invention provides a method for determining the susceptibility of a cell or a patient of interest to entering an autophagocytic state upon treatment with a drug. The invention also provides a method of determining susceptibility of a cell or patient to treatment with a drug. Entering an autophagocytic state is thought to be a tumour cell survival mechanism, whereby the tumour cell avoids apoptosis. The methods of the invention may therefore be helpful for determining whether a patient should be treated and for determining the prognosis upon drug treatment.

Biomarkers for prognosis

Biomarkers for prognosis

Biomarkers for prognosis

Owner:OXFORD UNIV INNOVATION LTD

Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same

ActiveUS20170096405A1Prevent goodConvenient treatmentOrganic active ingredientsNervous disorderAutoimmune conditionMedicine

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.

Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same

Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same

Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same

Owner:CHONG KUN DANG PHARMA CORP

Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same

ActiveUS10287255B2Prevent goodConvenient treatmentOrganic active ingredientsNervous disorderImmunologic disordersAutoimmune condition

A compound of formula (I), having histone deacetylase 6 (HDAC6) inhibitory activity,wherein X, Q, N, R1, R2, L, and n are as described, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.

Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same

Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same

Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same

Owner:CHONG KUN DANG PHARMA CORP

Selective HDAC6 inhibitors and uses thereof

InactiveUS9993459B2Organic active ingredientsNervous disorderHDAC6Cancer research

The present invention relates to selective Histone deacetylase 6 (HDAC6) inhibitors and compositions containing the same. Methods of treating diseases and conditions wherein inhibition of HDAC6 provides a benefit, like a cell proliferative disease, an autoimmune or inflammatory disorder, a neurodegenerative disease, or a combination thereof, also are disclosed.

Selective HDAC6 inhibitors and uses thereof

Selective HDAC6 inhibitors and uses thereof

Selective HDAC6 inhibitors and uses thereof

Owner:UNIV GENT

Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs

ActiveUS11311540B2High expressionEasy to identifyOrganic active ingredientsAntineoplastic agentsCancer cellOncology

Provided herein is a combination comprising an HDAC inhibitor and an IMiD for increasing interferon regulated gene expression or decreasing c-MYC gene expression in a cancer cell or tumor in a subject in need thereof. Increasing interferon regulated gene expression may result in increased recognition of tumors by innate or adaptive immune system and an increase in programmed cell death (apoptosis) gene expression, increasing apoptosis in cancer cells and tumors. The cells can be multiple myeloma cells or diffuse large B-cell lymphoma cells. Also provided are methods for treating myelodysplastic syndromes / acute myeloid leukemia (MDS / AML) or pathogen infections in a subject in need thereof comprising administering to the subject an effective amount of HDAC inhibitor and an IMiD. The HDAC inhibitor can be an HDAC6-selective inhibitor.

Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs

Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs

Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs

Owner:ACETYLON PHARMA

Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

ActiveUS10494355B2Prevent goodConvenient treatmentOrganic active ingredientsSenses disorderNervous systemNeoplasm

The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.

Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Owner:CHONG KUN DANG PHARMA CORP

1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors

InactiveUS20200339569A1Organic active ingredientsNervous disorderDitazoleMedicine

The invention relates to compounds of Formula (I) as described herein, useful as histone deacetylase 6 (HDAC6) inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy.

1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors

1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors

1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors

Owner:ORYZON GENOMICS SA

Double-target inhibitor as well as preparation method and application thereof

ActiveCN109761898AUnsatisfactory treatment effectHigh inhibitory activityOrganic active ingredientsOrganic chemistryElectronTumor cells

The invention discloses a double-target inhibitor as well as a preparation method and application thereof. The double-target inhibitor has a structure shown as a formula (I), wherein R1 is H, an electron-withdrawing group or an electron-donating group; R is alkyl; n is equal to 1 to 5. The double-target inhibitor provided by the invention can be used for selectively inhibiting HDAC6 and IC50 values on HDAC1 and HDAC8 are greater than 20 muM; the double-target inhibitor is used as a prodrug to be subjected to hydrolysis reaction in cells, and tubulin and an HDAC double-target inhibitor can be released; the inhibition activity of histone deacetylase on solid tumors is improved; the double-target inhibitor has a relatively good inhibition effect on tumor cells. The formula (I) is shown in thedescription.

Double-target inhibitor as well as preparation method and application thereof

Double-target inhibitor as well as preparation method and application thereof

Double-target inhibitor as well as preparation method and application thereof

Owner:QINGDAO UNIV

Methods and compositions for nucleic acid transfer into cells

InactiveUS20090069266A1Increase the gapIncrease gene expressionOrganic active ingredientsDrug compositionsHDAC6Gene transfer

The present invention provides compositions and methods for increasing the transfer of nucleic acids into cells. In particular, the present invention provides for the use of inhibitors of HDAC6, a cytoplasmic histone deacetylase present in mammalian cells by, for example, small molecules or siRNA treatment, in increasing gene transfer and/or expression in cells in vitro and in vivo for research and gene therapy applications.

Methods and compositions for nucleic acid transfer into cells

Methods and compositions for nucleic acid transfer into cells

Methods and compositions for nucleic acid transfer into cells

Owner:NORTHWESTERN UNIV

Tricyclic compound and application thereof

PendingCN113121527ANovel structurePrevent proliferationOrganic active ingredientsOrganic chemistryHDAC6Pharmaceutical medicine

The invention discloses a tricyclic compound and application thereof. The invention specifically discloses a compound as shown in a formula I or pharmaceutically acceptable salt thereof. The tricyclic compound disclosed by the invention has a very good inhibition effect on HDAC (histone deacetylase), especially HDAC6, has relatively good selectivity and can be used for inhibiting proliferation of various tumor cells.

Tricyclic compound and application thereof

Tricyclic compound and application thereof

Tricyclic compound and application thereof

Owner:SHANGHAI LITEDD CO LTD +1

New treatment for neurodegenerative diseases

InactiveUS20150184154A1Strong responseDecreasing autophagyHydrolasesGenetic material ingredientsMedicineHDAC6

The present application provides a method for treating a neurodegenerative disease in a subject characterised in that a therapeutically effective amount of a modulator of HDAC6 administered to said subject.

New treatment for neurodegenerative diseases

New treatment for neurodegenerative diseases

Owner:NOVARTIS FORSCHUNGSSTIFTUNG

Popular searches

Hematologic disease HDAC inhibitor Cancer Tetralin Metabolic disease Acute cardiovascular disease Neuro-degenerative disease Cardio vascular disease Blood disease Histone protein

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Try Eureka

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap